[
  {
    "ts": null,
    "headline": "The 1-Minute Market Report March 8, 2025",
    "summary": "The market was down 3.1% for the week and down 2.9% YTD. We are now back to where we started on election day in November 2024. Click to read.",
    "url": "https://finnhub.io/api/news?id=d8ad42d899997a51c529c74c7276d6fe19bb675ef00626dac18bebc4784cddc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741593240,
      "headline": "The 1-Minute Market Report March 8, 2025",
      "id": 133116991,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182894994/image_182894994.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "The market was down 3.1% for the week and down 2.9% YTD. We are now back to where we started on election day in November 2024. Click to read.",
      "url": "https://finnhub.io/api/news?id=d8ad42d899997a51c529c74c7276d6fe19bb675ef00626dac18bebc4784cddc3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges",
    "summary": "Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®. These lawsuits, filed across 30 countries, underscore the competitive nature of mRNA technologies and potential financial implications, possibly influencing Moderna's stock, which rose 15% last week. The broader market environment is also relevant, with the S&P 500 and Nasdaq logging a...",
    "url": "https://finnhub.io/api/news?id=b7bf9b4466b92d4864f17afe272e7b83ee3b19b12c52da89a918e5ec8280c4f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741567939,
      "headline": "Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges",
      "id": 133193267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®. These lawsuits, filed across 30 countries, underscore the competitive nature of mRNA technologies and potential financial implications, possibly influencing Moderna's stock, which rose 15% last week. The broader market environment is also relevant, with the S&P 500 and Nasdaq logging a...",
      "url": "https://finnhub.io/api/news?id=b7bf9b4466b92d4864f17afe272e7b83ee3b19b12c52da89a918e5ec8280c4f4"
    }
  }
]